ADA 2019 interviews

Kim Pfotenhauer considers whether the D2d trial has settled the question of the role of vitamin D in the prevention of type 2 diabetes (1:53).

John Wilding discusses how the results of the REWIND study add to our knowledge of the effects of the glucagon-like peptide-1 receptor agonist class in people with varying degrees of cardiovascular risk (3:37).

Nurse educator Lori Berard gives her view of how the REWIND trial can help clinicians working with people with type 2 diabetes (1:48).

Stephanie Amiel overviews her ADA highlights, including novel rapid-acting insulins and the sometimes surprising insights that technology offers into hypoglycemia (3:20).

Lori Berard gives an overview of the ADA session “Making a difference in five minutes: Interventions in diabetes for anyone.” (2:00)

PIONEER 6 lead investigator Mansoor Husain discusses the results of the trial, and how oral and injectable semaglutide compare and can be used in the clinic (4:40).

John Wilding outlines the key take-home message from the CAROLINA trial comparing the cardiovascular risk profile of the dipeptidyl peptidase-4 inhibitor linagliptin and the sulfonylurea glimepiride (0:37).

Sanjay Kalra tells us why he is so reassured by the findings of the CAROLINA trial pitting linagliptin against glimepiride (2:38).

Sanjay Kalra discusses the implications of the DUAL VIII trial, which looked at the effect of IDegLira versus glargine on the time to treatment intensification in people with type 2 diabetes (2:39).

John Wilding talks about research presented at the ADA Scientific Sessions looking at the management of type 1 diabetes in elite athletes (3:18).